<qa>  What is the name of the PROGRAMS IN TREATING PATIENTS WITHCLOFARABINE, CYTARABINE, AND FILGRASTIM FOLLOWED BY INFUSION OF NON-HLA MATCHED EX VIVO EXPANDED CORD BLOOD PROGENITORS IN TREATING PATIENTS WITH ACUTE MYELOID LEUKEMIA: 